Quantcast

Latest zolpidem Stories

2010-02-09 15:35:00

POINT RICHMOND, Calif., Feb. 9 /PRNewswire-FirstCall/ --Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that the first patent covering the composition and method of use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate, has been issued by the United States Patent and Trademark Office. Transcept announced the issuance of a Notice of Allowance for claims under the application for this patent, U.S. Patent Application...

2009-12-10 18:00:00

SAN DIEGO, Dec. 10, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that positive data from a clinical trial evaluating the abuse potential of lorcaserin were presented in a poster session at the 48th Annual Meeting of the American College of Neuropsychopharmacology. Data from the trial demonstrate that the risk for abuse associated with lorcaserin is very low. "Human abuse liability studies of the type done by Arena provide critical data to the FDA...

2009-12-08 07:04:00

BEVERLY HILLS, Calif., Dec. 8 /PRNewswire/ -- The Waismann Method, a pioneering medical opiate detoxification procedure, offers one of the most advanced medical procedures worldwide with the medical expertise and advanced technology to treat dependencies to Zolpidem, a prescription medication widely used for the short-term treatment of insomnia and prescribed under trade names including Ambien and Edluar. The Waismann Method of Rapid Ambien Detox involves a safe, medically-assisted...

2009-11-23 15:05:00

POINT RICHMOND, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). As previously announced, the Complete Response Letter, received by Transcept on October 28, 2009, indicated that the FDA...

2009-11-10 15:05:00

RICHMOND, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, at 2:10 p.m. Eastern Standard Time. A live audio webcast and replay of the presentation will be available on the Transcept investor webpage at www.transcept.com. About Transcept Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the...

2009-10-29 00:13:00

RICHMOND, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals (Nasdaq: TSPT) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). The NDA, submitted by Transcept in September 2008, seeks approval to market Intermezzo® for use as-needed for the treatment of insomnia when a middle of the night...

2009-09-08 09:30:00

SOMERSET, N.J., Sept. 8 /PRNewswire/ -- Meda Pharmaceuticals Inc. (Meda) today announced the commercial availability of EDLUAR(TM) (zolpidem tartrate sublingual tablets) in the United States. EDLUAR is indicated for the short-term treatment of insomnia characterized by difficulties with falling asleep. EDLUAR is the first available under-the-tongue formulation of zolpidem tartrate, which is the most prescribed treatment for insomnia. Zolpidem tartrate is also the active ingredient in...

2009-09-02 15:35:00

RICHMOND, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it will present at the BioCentury Thomson Reuters Newsmakers in the Biotechnology Industry Conference on Wednesday, September 16, 2009 at 11:00 am EDT. A live audio webcast and replay of the presentation will be available on the investor webpage at www.transcept.com. About Transcept Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the...

2009-08-26 16:05:00

RICHMOND, Calif., Aug. 26 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it will present at two upcoming healthcare investor conferences. Rodman & Renshaw 11th Annual Healthcare Conference on Wednesday, September 9, 2009, at 10:25 am EDT. Baird 2009 Health Care Conference on Thursday, September 10, 2009, at 10:00 am EDT. A live audio webcast and replay of the presentations will be available on the investor webpage at...

2009-08-18 06:35:00

RICHMOND, Calif., Aug. 18 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced plans to reduce operating expenses by eliminating certain staff positions following its recently announced License and Collaboration Agreement with Purdue Pharmaceutical Products to commercialize Intermezzo((R) )(zolpidem tartrate sublingual tablet) in the United States. Glenn A. Oclassen, President and Chief Executive Officer commented, "Our overall staffing needs have been...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related